In the fluvastatin XL group , the proportion of patients with moderate cardiovascular ( CV ) risk and high CV risk achieving their LDL-C treatment goals at endpoint was 50.0 % and 31.5 % respectively , while the proportion was 42.5 % and 24.5 % respectively in the fluvastatin IR group .